Skip to main content
Clinical Trials/KCT0001258
KCT0001258
Active, not recruiting
未知

A clinical trial to evaluate the pharmacokinetics of the fixed-dose combination of micronized fenofibrate and pitavastatin Ca under fed condition in healthy male volunteers

Hanlim Pharmaceutical0 sites40 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the circulatory system
Sponsor
Hanlim Pharmaceutical
Enrollment
40
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
Male

Investigators

Sponsor
Hanlim Pharmaceutical

Eligibility Criteria

Inclusion Criteria

  • 1\) Healthy male subjects age 19 to 55 at the screening visit
  • 2\) Body weight\=50kg and within Ideal body weight±20%
  • 3\) Subject who is judged to be eligible according to clinical laboratory tests including hematological examination, blood chemistry examination, urine analysis and
  • 4\) Subject who volunteerly determined to participate in and agreed to comply with precautions after totally understand the detailed explanations about this study

Exclusion Criteria

  • 1\) Subject with serious active cardiovascular, respiratory, hepatology, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease
  • 2\) Subject with symptoms of acute disease within 28days prior to study medication dosing
  • 3\) Subject with known for history which affect on the absorption, distribution, metabolism or excretion of drug
  • 4\) Subject with clinically significant active chronic disease
  • 5\) Subject with any of the following conditions in laboratoy test
  • i. AST(aspartate aminotransferase)or ALT(alanine transferase) \> upper normal limit X 1\.5
  • ii. Total bilirubin \> upper normal limit X 1\.5
  • iii. Renal failure with creatinine clearance \<50mL/min
  • iv. Creatinin phsphokinase \> upper normal limit X 2
  • 6\) Positive test results for hepatitis B virus surface antigen, anti\-hepatitis C virus antibody, human immunodeficiency virus antigen/antibody,venereal disease research laboratory test

Outcomes

Primary Outcomes

Not specified

Similar Trials